Board of Directors Unanimously Recommend Approving Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys Shareholders are encouraged to vote FOR Proposals 1, 2, and 3 by Calling 1-877-750-8310 IRVINE, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will host a Special Meeting of Stockholders of ReShape Lifesciences Inc. to be held at 11:30 am ET ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak alive in its next quarterly report? DaVita HealthCare (DVA) , which belongs to the Zacks Medical - Outpatient and Home Healthcare industry, could be a great candidate to consider.When looking at the last two reports, this kidney dialysis provider has recorded a strong streak of surpassing earnings estimates. The company has topped estimates by 7.82%, on average, in the last two quarters. ...

点击上图▲立即收听 " 18—35 岁年轻人的消费榜单前三位，分别是旅游、数码产品和保健养生。 " 文 / 巴九灵（微信公众号：吴晓波频道） "舌苔偏厚，体质寒湿，肝火旺，建议少吃辛辣、冰饮。" 下午时分，26岁的白领小陈对着手机摄像头伸出舌头，屏幕那端的AI医生瞬间给出了这样的反馈。 而看似戏谑的背后，实则是一种集体性的健康觉醒。 由国家统计局等发起的《中国美好生活大调查》显示，18—35岁年轻人的消费榜单前三位分别是旅游、数码产品和保健养生。另外根据知萌咨询 在今年3月的调研数据，Z世代平均每年在健康消费上的支出达到3250.7元。 这不，最近巨头们如火如荼的闪购战，让不少人真切体验了一把奶茶自由。网络上，关于"冰箱塞满奶茶""两天九杯冲上头"的分享不胜枚举，但也 敲响了年轻人的身体警钟。 在"求医AI"前，小陈刚好收到了动态血糖仪APP弹出的"血糖飙升"警告。 公开数据显示，中国咖啡消耗量近10年内增长了167%，消费者偏好带奶、带糖、带小料的花式咖啡；奶茶消费同样也是，超8成用户一周消费2— 3次，甚至高于3次，高频消费的同时还爱搭配软欧包食用。 当这样的"甜蜜轰炸"成为日常，直接催生了一个热词——咖 ...

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or a ...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and argenex SE (ARGX) . But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look.The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight com ...

Live Chat on The Biotech Forum has been dominated by discussion of covered call opportunities in recent quarters. To see what I and the other season biotech investors are targeting as trading ideas in real-time, just initiate your free trial into The Biotech Forum by clicking HERE .Today, I am putting DexCom, Inc. (NASDAQ: DXCM ) in the spotlight. The stock of this medical device concern got a bit of a temporary boost of 10% in late June when the Department of Health and Human Services announced itBret lead ...

Recursion Pharmaceuticals (RXRX) shares soared 5.8% in the last trading session to close at $5.84. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8% gain over the past four weeks.The sudden soaring of the stock price can be attributed to the postive investor mindset regarding the potential of Recursion's early-stage oncology pipeline being developed using its AI-driven platform technology. This biotechnology company is expected ...

Revvity (RVTY) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended June 2025. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The earnings report, which is expected to be released on July 28, might help the stock move higher if these key numbers are better than expectations. On ...

Key Takeaways JNJ beat Q2 estimates and raised full-year guidance on strong pharma performance. Innovative Medicine sales rose despite Stelara LOE, aided by key drugs and new launches. MedTech improvement was led by cardiovascular and surgical products, which offset China-related headwinds.Johnson & Johnson (JNJ) delivered strong second-quarter 2025 results, with both the top and bottom lines exceeding expectations.Despite the loss of exclusivity (“LOE”) of its multi-billion-dollar product, Stelara, J&J’s ...

Tandem Diabetes Care, Inc. (TNDM) has been on a downward spiral lately with significant selling pressure. After declining 27% over the past four weeks, the stock looks well positioned for a trend reversal as it is now in oversold territory and there is strong agreement among Wall Street analysts that the company will report better earnings than they predicted earlier.We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a ...